HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report.

Abstract
Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy.
AuthorsSonia Gupta, Amandeep Rakhra, Vinay Thallapally, Joseph Nahas
JournalIntractable & rare diseases research (Intractable Rare Dis Res) Vol. 10 Issue 2 Pg. 122-125 (May 2021) ISSN: 2186-3644 [Print] Japan
PMID33996358 (Publication Type: Case Reports)
Copyright2021, International Research and Cooperation Association for Bio & Socio - Sciences Advancement.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: